



Norgine announces a 17% increase in sales for 2004

2 February 2005

Norgine has announced that its sales in 2004 were €155m, an increase of 17% over 2003. This is the eighteenth consecutive year of double digit growth. Sales growth was led by Movicol® which saw a 34% increase in sales.

Commenting on the figures Peter Stein, Chief Executive Officer said “2004 represented another highly successful year for Norgine. Significant advances in sales were made in all our major markets and we continue to strengthen our sales and marketing organisation across Europe. 2005 promises to be another good year with strong growth expected from the existing product portfolio, supported by the launch of Oramorph® in a number of key markets”.

ENDS

Notes to editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for almost 100 years and has a presence in all the major European markets. The company employs 900 people, of which 350 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets eight products in its key therapeutic areas e.g. Movicol for the treatment of chronic constipation and faecal impaction, Klean-Prep® for bowel preparation prior to colonoscopy and Fivasa® for the treatment of ulcerative colitis and Crohn's disease.

Norgine has an active Research and Development effort and currently has nine products at various stages of clinical development including NRL994, a bowel preparation product. A European submission for NRL994 has already been filed and the company expects to submit an NDA in 2005.

Norgine has two manufacturing sites; Hengoed in the UK and Dreux, France.

Norgine's website is www.norgine.com

For further information, please contact:

Paul Pay, Vice-President, Business Development, Norgine

T: +44 (0)1895 453710

E: ppay@norgine.com

Louise Blakeborough, Chapter Five

T: +44 (0)1306 731800

E: lblakeborough@chapterfive.co.uk